Guggenheim Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12
Benzinga Newsdesk 12 months ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Michael Schmidt initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $12.
Guggenheim analyst Michael Schmidt initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $12.